Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial

Aims To evaluate clinical profiles and outcomes in patients with systolic heart failure ( HF ) with or without diabetes, and the efficacy and safety of ivabradine (heart rate‐lowering agent) with respect to diabetic status. Methods and results This is a post hoc analysis on patients in SHIFT , a randomized controlled trial in adults in sinus rhythm with systolic HF , left ventricular ejection fraction ≤35%, and resting heart rate ≥70 b.p.m....